GraniteShares YieldBOOST Biotech ETF (BIOY)

The yield you collect today is income forfeited tomorrow if the stock soars.

BIOY holds a basket of biotech companies and systematically sells covered call options against them. Each month or quarter, new calls are written at strike prices 5–10 percent out of the money. The premiums from those calls—paid by traders buying the right to purchase the fund’s shares at the strikes—are distributed to BIOY’s shareholders. The trade-off is stark: if biotech rallies strongly and the call strikes are breached, BIOY’s holders keep gains only up to the strike; anything beyond is captured by the call buyers.

How covered calls work inside the fund

A covered call is straightforward: you own stock, you sell someone the right to buy it at a fixed price at a future date, you pocket the premium. If the stock stays below that strike at expiration, you keep both the stock and the premium. If the stock rises above the strike, the buyer exercises; you sell the shares at the strike and miss the higher market price.

BIOY automates this on roughly 50 large biotech companies. Each month or quarter, the fund rolls new call options. The result: a monthly or quarterly income stream visibly higher than dividends alone. Where a standard biotech ETF might yield 1–2 percent, BIOY might yield 4–7 percent.

The volatility trap

Call premiums swing wildly with market fear. In calm markets, calls are cheap to write—holders collect little income. In volatile markets, calls are expensive—BIOY’s distributions spike. This is the trap: BIOY’s highest yields coincide with periods of market stress, when biotech volatility has exploded. That is precisely when the odds are highest that positions will be called away, or that the opportunity cost—missing a post-crisis rebound—is steepest.

GraniteShares and the fund structure

GraniteShares, a US investment advisor and ETF sponsor, manages BIOY to track a yield-enhanced version of the Nasdaq Biotechnology Index. The fund trades on the NASDAQ with moderate liquidity. The expense ratio is around 0.60–0.75 percent annually, covering the cost of the options programme. Part of the high distribution yield is not true dividend income but a return of capital—the premium you sold today, not earnings the company generated.

The real costs of the strategy

Concentration risk: BIOY holds roughly 50 large-cap biotech names, not the broader universe, to manage the options programme. If those 50 underperform, there is no diversification to cushion it.

Called-away stock: in a strong biotech bull market, BIOY’s positions are called away frequently, shrinking the fund and underweighting the best performers.

Volatility collapse: if market calm sets in, call premiums evaporate and distributions crash. A 6 percent yield may drop to 2 percent in months.

Opportunity cost: every dollar of call income today is a dollar that will not compound if the stock rallies 20 percent next year. In growth sectors like biotech, this drag compounds over long periods.

Who should consider BIOY

Investors seeking steady monthly income from biotech exposure, willing to cap upside. Retirees or endowments needing cash flow and indifferent to missing explosive gains. Not a growth fund; an income fund in biotech’s clothing.

A researcher should compare BIOY holdings against a standard biotech ETF, track which positions get called away frequently, and backtest the impact—then ask whether the extra current income justified the forgone gains.